BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPSCs

Cellectricon and Censo Launch Human iPSC-based Discovery Services for CNS and Pain Research

By

Cellectricon and Censo Biotechnologies Introduce a Joint Technology Access Program

High-quality Human iPSC-based discovery services for CNS and pain research.

Censo Biotechnologies and Cellectricon AB | January 26, 2017 – Cellectricon AB and Censo Biotechnologies Ltd are announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research. [Read more…]

Roslin Stem Cell Companies Combine to Create Censo Biotechnologies Group

By

Edinburgh, UK. 10 May 2016 — The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focused on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.

Censo Biotechnologies has extensive capacity to create and use induced Pluripotent Stem Cells (iPSCs) for drug discovery research with sites in Edinburgh and Cambridge, UK. The Company uses this capacity to produce stem cells from large diverse groups of individuals, so that drug development companies can understand how the efficacy of their drugs varies across the population. This underpins faster drug development and enables the right drug to be targeted to the right patient. [Read more…]

Axiogenesis Secures Funding for Market Expansion from Sino-German High-Tech Fund

By

Founded in 2001 and headquartered in Cologne, Germany, Axiogensis is one of a small number of companies specializing in induced pluripotent stem cell (iPSC) products. The company also has an American subsidiary that was founded in 2014 and is located in Philadelphia, Pennsylvania. Since its launch, the company has grown into a market leader for in vitro models of healthy and diseased cell types and tissue. [Read more…]

STEMCELL Technologies Partners with IMBA to Commercialize Brain Organoids
(‘Mini Brains’) for Researchers

By

In major news released today, STEMCELL Technologies announced that it has partnered with the Institute of Molecular Biotechnology (IMBA) in Vienna, Austria, to develop products for cerebral organoid culture for researchers worldwide.

Founded in 1993 and headquartered in Vancouver, Canada, STEMCELL Technologies is a diversified provider of stem cell research products. The company is known for utilizing strategic alliances to grow its dominance within the stem cell field. Current partnerships of STEMCELL Technologies include a licensing deal with the Wisconsin Alumni Research Foundation (WARF), iPS Academia Japan Inc., Salk Institute for Biological Sciences, and more.

To learn more, read the full press release released by STEMCELL Technologies, printed with permission from Sam Lloyd-Burton, Senior Product Marketing Manager, Neural and Pluripotent Stem Cell Biology, at STEMCELL Technologies.

[Read more…]

How iPSCs are becoming an Emerging Area of Stem Cell Research

By

Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and diverse market for iPSC research tools has emerged.

Included below is a ten-year history of iPSC grants (source: RePORT.NIH.gov), clinical trials (source: ClinicalTrials.gov), and scientific publications (source: PubMed.gov).

Each graph below suggests that the iPSC market is expanding. [Read more…]

BioInformant's World-Class Clients